ReviewHemaSphere
Immune Checkpoint Inhibition in Hodgkin Lymphoma.
Review in HemaSphere. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Recent updates in the therapeutic uses of Pembrolizumab: a brief narrative review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Review
- Checkpoint blockade therapy in Hodgkin lymphoma: improved response through combination with JAK inhibition.Signal transduction and targeted therapy · 2024Article
- Article
- Programmed Death Ligand 1 (PD-L1) Expression in Lymphomas: State of the Art.International journal of molecular sciences · 2024Review
- Review
- Precision Medicine in Therapy of Non-solid Cancer.Handbook of experimental pharmacology · 2023Review
- Histological Subtypes Drive Distinct Prognostic Immune Signatures in Classical Hodgkin Lymphoma.Cancers · 2022Article
- Aggressive behaviour of Hodgkin's-like lymphoma in a domestic ferret.Veterinarni medicina · 2021Article
- Immune-Checkpoint Inhibitors in B-Cell Lymphoma.Cancers · 2021Review
- Immunodeficiency-Related Lymphoid Proliferations: New Insights With Relevance to Practice.Current hematologic malignancy reports · 2020Review
- Immune-based Therapies for Hematological Malignancies: An Update by the EHA SWG on Immunotherapy of Hematological Malignancies.HemaSphere · 2020Article
- Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials.International journal of molecular sciences · 2020Review
- Targeting ADAM10 in Cancer and Autoimmunity.Frontiers in immunology · 2020Review
- Challenges and Opportunities for Childhood Cancer Drug Development.Pharmacological reviews · 2019Review
- The First Year of HemaSphere and Many More to Come.HemaSphere · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Intricate systems of checkpoints such as the programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) axis regulate adaptive immune responses to protect against tissue damage. However, diverse cancers can exploit these pathways to evade or suppress antitumor immunity, leading to tumor progression. Correspondingly, immune checkpoint inhibitors that block PD-1/PD-L1 signaling have shown marked therapeutic efficacy in certain cancers, such as Hodgkin lymphoma. Reed-Sternberg cells, the hallmark cells of Hodgkin lymphoma, commonly overexpress PD-1 ligands, and recent clinical trials have demonstrated impressive response rates with the PD-1 inhibitors nivolumab and pembrolizumab in relapsed or refractory Hodgkin lymphoma, leading to their FDA approval in this setting. Current efforts are underway to improve clinical responses by incorporating PD-1 inhibitors into earlier treatment regimens and identifying therapeutic agents that synergize with PD-1 inhibitors. This review summarizes our understanding of the PD-1/PD-L1 axis in Hodgkin lymphoma, recent clinical studies of anti-PD-1 monotherapy and promising combination immunotherapy in the pipeline.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.